Micuda, Stanislav
Poslední změna: 22.07. 2019

Research funding

The group received several scientic grants.
 
Období      Název grantu (číslo)                                                      Grantová agentura
2019-2021 Novel interventions for the treatment of triglycerides, cholesterol and bile acids diseases with human CAR ligands (19-14497S) GAČR
2018-2020 Role of iron depletion and Mrp2 deficiency for development of estrogen-induced cholestasis (556218) GAUK
2018-2020 Effect of cardiovascular drugs on the development of non-alcoholic steatohepatitis (346218) GAUK
2018-2021 PERSONMED - The centre for personalized medicine development in age-dependend disorders  (CZ.02.1.01/0.0/0.0/16_048/0007441) MŠMT EDRF
2017-2019 Dynamics of nuclear receptor-mediated gene regulation:implement for the understanding of detoxification functions and optimization of therapy (GA17-06841S) GAČR
2015-2017 Tissue and soluble endoglin and their importance in endothelial dysfunction and atherogenesis in vivo and in vitro (GA15-24015S) GAČR
2012-2015 Increasing of the R&D capacity at Charles University through new position for graduates of doctoral studies (Postdoci II UK) - CZ.1.07/2.3.00/30.0061 MŠMT-OP VVV
2012-2014 Breast cancer pathophysiology and its modulation by plant anticancer agents boldine and alpha-tomatine (NT13473) IGA
2009-2011 The study of potential importance of epigallocatechin gallate in the prevention and treatment of the liver injury caused by intrahepatic and extrahepatic cholestasis (116807) GAUK
2008-2010 The study of the potential therapeutic importance of pravastatin in the treatment of the liver injury caused by acute and chronic extrahepatic cholestasis and biliary cirrhosis in rats. (122408). GAUK
2005-2009 COST B.25.10 (1P05OC062): Physiologically based prediction of pharmacokinetics prior to in vivo studies: Focus on hepatic and renal elimination.  COST
2005-2007 Cytochrome P450 3A4 and multidrug resistance proteins MDR1 and MRP2 as a major cause of drug-drug interactions at the level of drug elimination from organism (92/2005/C) GAUK
2002-2004 Evaluation of changes in MRP2 expression on the canalicular membrane of hepatocytes and their influence on liver methotrexate elimination (89/2002/C/LFHK) GAUK
2000-2005 COST B.15.30. Prediction of metabolic drug-drug interactions based on in vitro experiments COST
1997-1999 In vivo evaluation of CYP3A4 activity (57/1997/C) GAUK